Abstract P034 – Table 1. Swallowability/acceptability questionnaire outcomes

Parameter	Current ARV treatmenta (N = 27)	Screening placebo (N = 27)	D/C/F/TAF placebo (N = 27)	Darunavir/cobicistat placebo (N = 27)
How difficult/easy to swallow tablet, n (% to cumulative %)
Very easy	18 (66.7% to 66.7%)	12 (44.4% to 44.4%)	17 (63.0% to 63.0%)	16 (59.3% to 59.3%)
Moderately easy	5 (18.5% to 85.2%)	6 (22.2% to 66.7%)	3 (11.1% to 74.1%)	4 (14.8% to 74.1%)
Slightly easy	2 (7.4% to 92.6%)	2 (7.4% to 74.1%)	4 (14.8% to 88.9%)	5 (18.5% to 92.6%)
Neither difficult nor easy	2 (7.4% to 100%)	1 (3.7% to 77.8%)	1 (3.7% to 92.6%)	2 (7.4% to 100%)
Slightly difficult	0	4 (14.8% to 92.6%)	1 (3.7% to 96.3%)	0
Moderately difficult	0	0	0	0
Very difficult	0	2 (7.4% to 100%)	1 (3.7% to 100%)	0
Swallowing acceptability, n (%) (95% CI)
Easyb	27 (100%)	21 (77.8%)	25 (92.6%)	27 (100%)
(87.2% to 100%)	(57.7% to 91.4%)	(75.7% to 99.1%)	(87.2% to 100%)
Difficultc	0 (0.0%)	6 (22.2%)	2 (7.4%)	0 (0.0%)
(0.0% to 12.8%)	(8.6% to 42.3%)	(0.9% to 24.3%)	(0.0% to 12.8%)
Swallowing acceptability should tablet be taken once daily over a longer period, n (% to cumulative %)
Good to take	14 (51.9% to 51.9%)	14 (51.9% to 51.9%)	15 (55.6% to 55.6%)
Acceptable	9 (33.3% to 85.2%)	11 (40.7% to 92.6%)	12 (44.4% to 100%)
Not acceptable	4 (14.8% to 100%)	2 (7.4% to 100%)	0

^aall patients received ≥1 FDC in their current antiretroviral regimen, most commonly elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (12 [44.4%] patients), rilpivirine/emtricitabine/tenofovir disoproxil fumarate, dolutegravir/abacavir/lamivudine and abacavir/lamivudine (4[14.8%] patients each).

^bEasy = ‘Very easy’, ‘Moderately easy’, ‘Slightly easy’, ‘Neither difficult nor easy’.

^cDifficult = ‘Slightly difficult’, ‘Moderately difficult’, ‘Very difficult’.

95% CI – Clopper‐Pearson exact confidence interval for binomial proportion.